drugset / Trial / NCT00150566

Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood

NCT00150566 ↗

Phase 3 Completed 460 enrolled Shire
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test how well higher doses of lanthanum carbonate reduce the pre-dialysis level of serum phosphorus in subjects undergoing dialysis due to end stage renal disease.

Timeline

Start
2004-02-09
Primary completion
2005-10-08
Completion
2005-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanthanum Carbonate Other / unclassified 3000 mg —
Subject Lanthanum Carbonate Other / unclassified 3750 mg —
Subject Lanthanum Carbonate Other / unclassified 4500 mg —